Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Approved to Start China Trial of HDAC6 Inhibitor

publication date: Mar 13, 2019

CStone Pharma (Suzhou) was approved to start a China Phase I trial of its histone deacetylase 6 (HDAC6) selective inhibitor. The multi-center, Phase I dose escalation study will be conducted simultaneously in China and Australia in patients with advanced solid tumors and relapsed or refractory multiple myeloma. HDAC6 is the ninth CStone candidate to begin trials in China. At present, there are no other HDAC6 inhibitors approved for China use. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.